The HARMONY Trial
Open Access
- 1 October 2015
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation: Arrhythmia and Electrophysiology
- Vol. 8 (5), 1048-1056
- https://doi.org/10.1161/circep.115.002856
Abstract
Background—: Atrial fibrillation (AF) requires arrhythmogenic changes in atrial ion channels/receptors and usually altered atrial structure. AF is commonly treated with antiarrhythmic drugs; the most effective block many ion channels/receptors. Modest efficacy, intolerance, and safety concerns limit current antiarrhythmic drugs. We hypothesized that combining agents with multiple anti-AF mechanisms at reduced individual drug doses might produce synergistic efficacy plus better tolerance/safety. Methods and Results—: HARMONY tested midrange ranolazine (750 mg BID) combined with 2 reduced dronedarone doses (150 mg BID and 225 mg BID; chosen to reduce dronedarone’s negative inotropic effect—see text below) over 12 weeks in 134 patients with paroxysmal AF and implanted pacemakers where AF burden (AFB) could be continuously assessed. Patients were randomized double-blind to placebo, ranolazine alone (750 mg BID), dronedarone alone (225 mg BID), or one of the combinations. Neither placebo nor either drugs alone significantly reduced AFB. Conversely, ranolazine 750 mg BID/dronedarone 225 mg BID reduced AFB by 59% versus placebo ( P =0.008), whereas ranolazine 750 mg BID/dronedarone 150 mg BID reduced AFB by 43% ( P =0.072). Both combinations were well tolerated. Conclusions—: HARMONY showed synergistic AFB reduction by moderate dose ranolazine plus reduced dose dronedarone, with good tolerance/safety, in the population enrolled. Clinical Trial Registration—: ClinicalTrials.gov ; Unique identifier: NCT01522651.Keywords
This publication has 44 references indexed in Scilit:
- 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive SummaryCirculation, 2014
- Heart Disease and Stroke Statistics-2014 Update A Report From the American Heart AssociationCirculation, 2014
- Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conferenceEP Europace, 2013
- Rate versus rhythm control for management of atrial fibrillation in clinical practice: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registryAmerican Heart Journal, 2013
- Real-Life Observations of Clinical Outcomes With Rhythm- and Rate-Control Therapies for Atrial Fibrillation: RECORDAF (Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation)Journal of the American College of Cardiology, 2011
- Pathophysiological Mechanisms of Atrial Fibrillation: A Translational AppraisalPhysiological Reviews, 2011
- Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)European Heart Journal, 2010
- Practice Patterns Among United States Cardiologists for Managing Adults With Atrial Fibrillation (from the AFFECTS Registry)The American Journal of Cardiology, 2010
- Secular Trends in Incidence of Atrial Fibrillation in Olmsted County, Minnesota, 1980 to 2000, and Implications on the Projections for Future PrevalenceCirculation, 2006
- Prevalence of Diagnosed Atrial Fibrillation in AdultsJama-Journal Of The American Medical Association, 2001